Patents by Inventor Shailesh Dudhgaonkar

Shailesh Dudhgaonkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies Binding to Human PAD4 and Uses Thereof
    Publication number: 20240132622
    Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.
    Type: Application
    Filed: July 20, 2023
    Publication date: April 25, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
  • TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS LUPUS ERYTHEMATOSUS
    Publication number: 20230310408
    Abstract: Disclosed is method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 10, 2021
    Publication date: October 5, 2023
    Inventors: Gary L. Schieven, Shailesh Dudhgaonkar
  • TREATING RHEUMATOID ARTHRITIS
    Publication number: 20230310409
    Abstract: Disclosed is a method of treating rheumatoid arthritis, comprising administering to a patient a therapeutically effective dose of a TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TNF? inhibitor.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 5, 2023
    Inventors: Gary L. Schieven, Shailesh Dudhgaonkar, Michael Louis Doyle